Achieve Life Sciences, INC Form 4 insider transactions

Thomas Sellig, a Director of Achieve Life Sciences, Inc., reported multiple transactions in common stock on July 27, 2026.

Christopher Nathan Martin, a Director of Achieve Life Sciences, Inc., reported multiple transactions in common stock on July 27, 2026.

Aaron Royston, a Director of Achieve Life Sciences, Inc., reported multiple transactions in common stock on July 27, 2026.

Reid Alexander Waldman, a Director of Achieve Life Sciences, Inc., reported multiple transactions in common stock on July 27, 2026.

Richard Alistair Stewart, a Director of Achieve Life Sciences, Inc., reported multiple transactions in common stock on July 27, 2026.

Jeffrey S Farrow, a Director of Achieve Life Sciences, Inc., reported multiple transactions in common stock on July 27, 2026.

Nancy R. Phelan, a Director of Achieve Life Sciences, Inc., reported multiple transactions in common stock on July 27, 2026.

Achieve Life Sciences, Inc. reports that Director Reid Alexander acquired stock options with an exercise price of $5.24, vesting over 36 months.

Jeffrey S. Farrow, a Director at Achieve Life Sciences, Inc., acquired stock options on May 29, 2026, as detailed in a recent SEC Form 4 filing.

Director Christopher Martin acquired 47,250 stock options with an exercise price of $5.59, vesting over 36 months starting May 11, 2026.

CEO Andrew D. Goldberg was granted over 17 million shares in restricted stock units, stock options, and performance-based awards.

Achieve Life Sciences' Chief Medical Officer, Mark Rubinstein, was granted 180,000 stock options with an exercise price of $4.36 per share.

ACHIEVE LIFE SCIENCES, INC. Chief Financial Officer Mark K. Oki was granted 180,000 stock options with an exercise price of $4.36, vesting over four years.

Achieve Life Sciences' Chief Commercial Officer, Jaime Xinos, was granted 180,000 stock options with an exercise price of $4.36, vesting over four years.

Achieve Life Sciences' Chief Operations Officer, Craig Donnelly, was granted 180,000 stock options with an exercise price of $4.36.

Achieve Life Sciences CEO Richard Alistair Stewart was granted 645,000 stock options with an exercise price of $4.36, vesting over four years.

ACHIEVE LIFE SCIENCES, INC. Principal Accounting Officer Jerry Wan was granted 70,300 stock options with an exercise price of $4.36, vesting over four years.

Achieve Life Sciences' Chief Legal Officer, Erik Atkisson, was granted 250,000 stock options with an exercise price of $4.78, vesting over four years.

Achieve Life Sciences' Chief Operations Officer, Craig Donnelly, was granted 50,000 stock options with an exercise price of $3.1, vesting over four years.

Achieve Life Sciences CFO Mark Oki acquired 168,000 shares through PRSU settlement and sold 50,060 shares to cover tax obligations.

Achieve Life Sciences CEO Richard Stewart acquired common stock through PRSU settlement and subsequently sold a portion to cover tax obligations.

ACHIEVE LIFE SCIENCES, INC. Chief Financial Officer Mark Oki earned 168,000 performance restricted stock units after meeting specific company performance criteria.

ACHIEVE LIFE SCIENCES CEO Richard Stewart earned 297,500 performance-based restricted stock units after the company met specific performance criteria.

ACHIEVE LIFE SCIENCES' Principal Accounting Officer, Jerry Wan, acquired common stock through performance restricted stock unit settlements and subsequently sold shares to cover tax obligations.

Achieve Life Sciences Director Thomas Braxton King acquired 455,000 shares through PRSU settlement, increasing his direct beneficial ownership by 315,142 shares after tax withholding.

Achieve Life Sciences' President & CMO, Cindy Jacobs, settled 110,000 performance restricted stock units and sold 27,629 shares for tax obligations.

Achieve Life Sciences' Chief Commercial Officer, Jaime Xinos, exercised performance restricted stock units and sold a portion of the resulting shares to cover tax obligations.

Achieve Life Sciences, Inc. Director Kristen B. Slaoui was granted 31,500 stock options with an exercise price of $3.83, vesting fully by June 2026.

Achieve Life Sciences, Inc. Director Nancy R. Phelan was granted 31,500 stock options with an exercise price of $3.83, vesting by June 2026.

Achieve Life Sciences, Inc. Director Thomas Sellig was granted 31,500 stock options with an exercise price of $3.83, vesting by June 2026.